Compare Dyne Therapeutics Inc. Common Stock (DYN) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs McDonald's Corp — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while McDonald's Corp trades at $238.94 (market cap $166.87B). The key difference: McDonald's Corp is far larger — about 58.3× Dyne Therapeutics Inc. Common Stock's market cap, and McDonald's Corp pays a 3.27% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and McDonald's Corp for 165 Days on average.
| DYN | MCD | |
|---|---|---|
Market Cap | $2.86B | $166.87B |
Volume | 3,341,579 | 4,543,119 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $341.06 |
52-Week Low | $14.60 | $230.88 |
Typical Hold Time | 0 Days | 165 Days |
Enterprise Value | $2.18B | $220.64B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
McDonald's (MCD) trades at $235.65, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 EPS of $3.38, beating expectations, and maintains robust profitability with a 31.72% net income margin. Recent news highlights McDonald's new 'NEXT' growth strategy focusing on automation and menu innovation to win back customers amid competitive pressures.
The stock offers a compelling long-term opportunity with 58.7% analyst buy ratings and a $284.70 consensus price target, representing 21% upside. Key risks include inflationary pressures on franchisee margins and high debt levels. The current valuation at 19.16x P/E appears reasonable given the company's stable cash flows and dividend consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
